Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel monoclonal antibodies for the treatment and diagnosis of cancer. The company is pursuing multiple company and investigator-sponsored clinical programs with its lead immunotherapy candidate bavituximab including the SUNRISE Phase III trial in patients with second-line non-small cell lung cancer. Other indications include front-line non-small cell lung, liver, breast and rectal cancers as well as melanoma. The company is also investigating an imaging agent that represents a potential new approach to imaging cancer. Peregrine has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com) which provides development and biomanufacturing services for both Peregrine and outside customers.
Type
Public
HQ
Tustin, US
Founded
1981
Employees
211 (est)
Peregrine Pharmaceuticals was founded in 1981 and is headquartered in Tustin, US

Peregrine Pharmaceuticals Locations

Tustin, US

Peregrine Pharmaceuticals Metrics

Peregrine Pharmaceuticals Summary

Market capitalization

$74.6 M

Closing share price

$0.291
Peregrine Pharmaceuticals's current market capitalization is $74.6 M.

Peregrine Pharmaceuticals Financials

Peregrine Pharmaceuticals's revenue is $44.7 M in FY, 2016 which is 66.86% increase from the previous period.
FY, 2014FY, 2015FY, 2016

Revenue

$22.4 M$26.8 M$44.7 M

Gross profit

$9.18 M$11.2 M$21.4 M

Operating income

$-35.7 M$-50.5 M$-56.4 M

Operating expense total

$26.5 M$39.3 M$35 M

Net Income

$-35.4 M$-50.4 M$-55.7 M

Operating cash flow

$42.3 M$-9.49 M$-6.59 M

    Peregrine Pharmaceuticals Market Value History

    Peregrine Pharmaceuticals News

    Peregrine Pharmaceuticals Company Life

    You may also be interested in